Canadian Agency For Drugs And Technologies In Health Case Study

Canada has spent 17.08% of its total health spending in pharmaceuticals justifying Canada’s vision and efforts of having the healthiest citizens in the world. Health Canada is responsible for granting permission of a new drug or health technology in Canada under the Federal Food and Drugs Act. Health Canada’s assessments are based on the scientific safety and efficacy of the drug and even cost-effectiveness assessments are performed, are not taken into consideration or if similar medication already exist in the market for the tackle of the same disease. To continue, the national HTA bodies are responsible for making recommendations to the public funds for coverage and reimbursement (Khoury et al, 2011).

Yet, Canada’s pricing approvals are
In the words, CADTH’s objective is the integration of suitable and effective new health technologies in the healthcare system of Canada in the ground-floor of precise, consistent and evidence-based information. Nonetheless, CADTH is not only making appraisals, but also provide formulary listing recommendations to the publicly funded drug plans in Canada except Quebec through the Common Drug Review (CDR)-only for non-cancer drugs- and identifies agile best practices for drug prescriptions through the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) (INAHTA, 2016). The pan-Canadian Oncology Drug Review (pCODR) is a programme of CADTH making reimbursement recommendations to Canada’s federal, provincial and territorial governments (except Quebec) for cancer drug funding decisions. Respectively, the CADTH Canadian Expert Drug Advisory Committee (CEDAC) is a team of experts, that provide coverage and reimbursement recommendations to health insurers for drugs, while the CADTH Canadian Expert Review Committee (pERC) is a team composed of medical oncologists, physicians, patients who are
Hence, pharmaceutical companies are submitting a fully consistent and scientifically based review to CDR and all the participating institutions, including the federal (Non-Insured Health Benefits, the Department of National Defense, Veterans Affairs Canada, the Royal Canadian Mounted Police and Correctional Service Canada), provincial (all provinces, except Quebec) and territorial (Northwest Territories, Yukon, Nunavut). CEDAC is making the final decision of whether a drug should be listed, not be listed or listed under restrictions to the drug plans. Once the decision is announced, it is each public’s drug fund decision of whether the drug will be included in the plan or